Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

"It's beyond ironic that pain management patients are blamed for a lack of self-control in becoming addicted when doctors are fully aware that potent synthetic narcotic drugs strip people of the ability to make the right choices. After all, we don't leave addiction and find recovery because our life was pleasant on the drugs we didn't choose but became our choice out of necessity. Cannabis doesn't do this to people. It heals our bodies and minds; it soothes our souls." -Mike Robinson, Founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

"Within each of us is an intricate network of receptors cannabis acts on to bring about its therapeutic effects. This network is called the endocannabinoid system (ECS), and it’s made up of many different components: Receptors: CB1 and CB2 are the most well-studied, but many others are known as GPRs and TRPVs. Endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2AG), made by your body and attached to CB1 and CB2 receptors, but others often remain unspoken. Enzymes FAAH and MAGL, to name 2 of them – which break down AEA and 2AG. Your endocannabinoid tone reflects how these components act together to bring about balance within your unique ECS – but it goes beyond that as our ECS modulates Homeostasis. This tone also encompasses the levels of endocannabinoids in your body and the rate at which they’re made and metabolized or broken down. ECS Tone also considers the density of receptors in your brain and beyond and whether or not they’re being adequately fed. It’s a complex subject that’s still under investigation." -Mike Robinson, Founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

"I'm a 5x Cancer Survivor now who used Cannabinoid Medicine as the primary (and only) treatment modality for years, with complete remission since 2/2019 after a Triple stage 4 battle. Immunosuppressants failed, and chemo/radiation wasn't an option after a prior paralysis from it in 2003. From 2022 through 2024, I fought and won again, taking out the root cause of it that appears to have been feeding Cancers in me for quite some time, possibly since the beginning. Not only did I live through the years - even decades of fighting, but life was also thriving throughout it due to the plant. I healed through and through, even quitting opioids after 24 years. I was able to stay away from opioids for the most part in this most recent battle and am in complete remission again. One more PET is scheduled, but it is anticipated to study organs and tissue for damage or inflammation from a drug interaction; the tracer is being used to detect cancer 'just in case.' Nature in many forms, including Cannabis, did the trick; there's no debate. Other people may have different stories, but it was a plant and a change in my life. Diet and exercise are far more critical than most consider them." -Mike Robinson, Founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

"Acidic Cannabinoids brought me to the point in life I'm at, to be able to fight severe issues and survive. My immune system is so strong right now as we review labs and imaging; my Oncologist stated I have a 'self-healing body'; he said that we all do, but most of us are missing vital nutrients in our diets, which is why he gives my diet and supplements credit for my survival. It's incredible to hear that, and sharing this is so important as people all over the world are using Cannabis as medicine in various ways - some having great success and others needing to find a balance in it all. Many lose efficacy with THC like I did, and some gain it back through learning about ECS Balance Control. I teach others how I made it happen for me. I bolstered my system to fight the Wars I've gone through in health in 2023 and 2024 alone, to come out still standing. Cannabinoids, Alkaloids, and so many supplements are used - a ton of rare aminos. I quit the Opioid Addiction in 2019, and I found that THC wasn't always my friend. I started working heavily with people on ECS Balance, fighting this annoying T Break stuff. After all, starvation isn't how we diet; we change what we eat - we adjust. If I starved my body from all of the supplements I've used in the past year, I wouldn't be here typing. That statement alone makes the "T Break" pretty ridiculous. We used to run out of weed due to scarcity, and that caused people to take short breaks but no 'T Break'—we went looking for roaches, scraped bongs and pipes, and got a few pinner joints from a friend when we were bone dry out of weed. Nobody ever said in 1970, 1980, or 1990 - or even in 2010: "I'm going to purposely not smoke weed so I can get high". The whole statement makes no sense, and from a research angle, it shows that ECS researchers are still yet to mature, and most cannabinoid medicine research is still based on isolates - stuff few of us use." -Mike Robinson, Founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

Review of the 2024 Study "Patterns of Use and Withdrawal Syndrome in Dual Cannabis and Tobacco Users" - There are several research studies tied together that focus on the overlapping use of cannabis and tobacco among individuals with cannabis use disorder (CUD) who are seeking treatment. The study investigates patterns of use, withdrawal symptoms, and how these factors affect treatment outcomes. A key innovation is using a gamified web app to monitor participants’ cannabis and tobacco use in real-time. This provides valuable data while interactively engaging users. The study aims to uncover the complex relationship between these substances and help design better interventions. The project has six main objectives, including identifying different usage patterns, monitoring withdrawal symptoms, and validating tools like the "Cannabis Withdrawal Checklist" for the Spanish population. In the first phase, researchers worked with patients, clinicians, and developers to co-design the web app, ensuring it meets user needs. In the second phase, 150 participants will use the app daily over six weeks to report their usage, withdrawal symptoms, and motivation to quit. The third phase will focus on evaluating the app’s usability and effectiveness. Early findings indicate that withdrawal symptoms, such as irritability, anxiety, and sleep disturbances, are common among both cannabis and tobacco users. Dual users often experience more severe symptoms than those using cannabis alone, which complicates the quitting process and increases the likelihood of relapse. This research points a finger towards the use of tobacco after cessation of Cannabis as a critical factor. We need to understand better how these substances interact. The study will identify factors that could improve treatment outcomes by documenting these symptoms in real-time. This data is critical for tailoring support strategies to the unique needs of dual users. Current CUD treatment programs often overlook the role of tobacco smoking, even though dual use appears to worsen withdrawal symptoms and complicate quitting efforts. This study highlights the need for integrated treatment approaches that address both substances simultaneously, potentially reducing relapse rates and improving outcomes. These insights could help clinicians develop more comprehensive and effective programs. Without a doubt, there's a long path ahead to quantify much of the research on CUD, as it has failed to include other substances the person was using with Cannabis, and many have far-reaching conclusions to date that seem to focus on a plant instead of the ECS. It's not surprising that nicotine plays a factor in cases of CUD as it stimulates the release of dopamine, a neurotransmitter associated with pleasure and reward, in critical areas of the brain's reward system pathways. -Mike Robinson, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC) Study: https://lnkd.in/gJgcgK-6

In November 2024, researchers published the study "Alterations of Endocannabinoid Signaling and Microglia Reactivity in the Retinas of AD-like Mice Precede the Onset of Hippocampal β-Amyloid Plaques" in the Journal of Neurochemistry. The study explored how the retina, often called a "window to the brain," could reveal early signs of Alzheimer’s disease (AD). The team examined endocannabinoid system (ECS) changes and microglial activity—immune cells of the nervous system—in a mouse AD model before significant brain changes, like β-amyloid plaques, developed. They focused on how these processes could contribute to neuroinflammation and oxidative stress, which are hallmark early events in Alzheimer’s pathology. They focused on 12-month-old mice, a stage when β-amyloid plaques have not yet formed in the brain. Using advanced lab techniques, they analyzed the retinas of these mice for signs of inflammation, changes in ECS components, and oxidative stress markers. Their work revealed increased microglia, indicating early retinal inflammation and elevated oxidative stress, but no significant neuronal degeneration or retinal thinning. The study found key alterations in the ECS, particularly in the levels of 2-arachidonoylglycerol (2-AG), an important signaling molecule. The researchers discovered a significant decrease in 2-AG levels in the retinas of AD-like mice, accompanied by an increase in the enzyme MAGL, which breaks down 2-AG. This imbalance, combined with increased levels of the CB2 receptor (linked to inflammation), suggests the ECS is dysregulated in AD. Interestingly, these changes occurred in the retina before β-amyloid plaques appeared in the brain, reinforcing that the retina reflects early Alzheimer ’s-related changes. The study also highlighted the role of microglia, immune cells in the retina that can influence inflammation and neuronal health. In AD-like mice, microglia numbers were significantly higher compared to healthy mice, suggesting these cells are reacting to early signs of damage or stress. Despite this, there were no significant changes in glutamate levels—a neurotransmitter often linked to cell damage—indicating that retinal neurons might still function normally at this stage. These findings underscore the promising potential of the retina as a non-invasive tool for early AD detection, offering hope for identifying the disease before severe brain damage occurs. By pinpointing ECS dysregulation and inflammation as early markers, this study paves the way for the development of novel therapies that target these pathways to potentially slow or prevent AD progression. -Mike Robison, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC) Study: https://lnkd.in/ghyBBPHC

Did you know we have less OLDA as we get older? Read/Learn/Share: N-oleoyl dopamine (OLDA) is a bioactive lipid that bridges the Endovanilloid system (EVS) and Endocannabinoid system (ECS) through its actions on TRPV1 channels and cannabinoid (CB) receptors. This dual activity positions OLDA as a critical regulator of inflammation, pain, neuroprotection, and immune modulation. A lack of OLDA in the system can upset the delicate ECS Balance we seek. OLDA is naturally produced in the body as part of the acyl-dopamine family. It is synthesized through the enzymatic conjugation of dopamine, a key neurotransmitter, and oleic acid, a fatty acid abundant in cell membranes. Factors such as dietary intake of oleic acid (from foods like olive oil and nuts), dopamine availability influenced by neurological activity, and physiological stress or injury can impact OLDA production. As an endogenous molecule, OLDA plays a role in maintaining homeostasis, particularly in modulating pain, inflammation, and immune responses. Its action on TPRV and CB receptors: TRPV1 Activation: Enhances calcium signaling, modulating pain, inflammation, and neurogenic responses. Supports gut health and vascular function. CB1 Receptor: Promotes neuroprotection, synaptic plasticity, and analgesia. CB2 Receptor: Regulates immune responses, suppressing inflammation and oxidative stress. Synergy: OLDA’s concurrent TRPV1 and CB activation creates a unique balance of local (TRPV1) and systemic (CB) effects, offering neuroprotective and anti-inflammatory benefits. Potential Health Benefits of having a balanced system with ample OLDA: Anti-inflammatory: Reduces cytokines (TNF-α, IL-1β) and oxidative stress, aiding conditions like arthritis, IBD, and sepsis. Pain Relief: Modulates nociceptive signaling, effective for neuropathic pain, migraine, and chronic pain. Neuroprotection: Shields against Alzheimer’s, Parkinson’s, and oxidative damage in the CNS. Mood Regulation: Balances neurotransmitters, alleviating anxiety and depression. Metabolic Health: Improves energy balance and lipid metabolism, aiding in weight management and diabetes prevention. Immune Modulation: Suppresses autoimmune conditions like lupus and psoriasis. Cardiovascular Health: Promotes vasodilation and protects against hypertension and atherosclerosis. Cancer Support: Potential in regulating tumor growth via TRPV1. To increase its levels, focus on a diet rich in oleic acid (found in olive oil, avocados, and nuts) to ensure a steady supply of its fatty acid precursor. Supporting dopamine production through regular exercise, stress reduction, and a diet containing tyrosine-rich foods (like fish, eggs, and dairy) will enhance its creation in the nervous system. OLDA’s ability to modulate TRPV1 and CBRs makes it a promising candidate for treating inflammation, neurodegeneration, pain, and immune disorders. -Mike Robinson, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

In an intensive study, researchers from Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center reported that after six months of treatment, 80% of participants with Autism reported some improvement from cannabinoid use. Patients' improved quality of life, mood, and ability to perform activities of daily living were assessed before treatment and at six months. 31.3% of patients reported a good quality of life before treatment initiation. At six months, good quality of life more than doubled to 66.8%. Positive mood was reported as 42% before treatment and 63.5% after six months. Other aspects of independence and quality of life were assessed, such as the ability to dress and shower independently. This improved significantly after cannabis treatment. Only a quarter (26.4%) reported no difficulty before the treatment, while 42.9% improved their ability to dress and shower independently at six months. The study also showed that cannabis oil medication significantly improved sleep and concentration. Good sleep and concentration were reported by 3.3% and 0%, respectively, at the outset, compared to 24.7% and 14% during active treatment. Dr. Victor Novack of the BGU-Soroka Clinical Cannabis Research Institute said: “While this study suggests that cannabis treatment is safe and can improve ASD symptoms and improve ASD patients’ quality of life, we believe that more double-blind placebo-controlled trials are crucial for a better understanding of the cannabis effect on ASD patients." Cannabis for Autism, it's a beautiful thing! -Mike Robinson, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC) study link: https://lnkd.in/ertzmi6

Q. Does Anger cause us to lose endocannabinoids? A: YES. Choosing not to react to anger or other intense emotions can help restore the Endocannabinoid System (ECS) by preserving the endocannabinoid tone. Our body’s endocannabinoids—like anandamide and 2-AG—are critical for regulating mood, stress, pain, and overall homeostasis. When we respond to anger or other stressors with intense emotion, we consume these endocannabinoids at a higher rate, depleting the ECS of essential molecules. This depletion can disturb our endocannabinoid tone, the balance that is vital for optimal ECS functioning. This is what Anger can do: Lower Endocannabinoid Consumption: Anger and other stress responses cause endocannabinoid release as the body counteracts heightened stress. When we choose not to react to anger, the body has less need to produce and release endocannabinoids like anandamide. This helps to conserve these molecules, supporting a balanced ECS and preventing the depletion of endocannabinoid reserves. Reduced Demand on CB1 and CB2 Receptors: By conserving endocannabinoids, we reduce overstimulation of CB1 and CB2 receptors, which mediate mood, stress, and pain responses. When anger is managed or avoided, these receptors remain more balanced, which protects their function and may contribute to better mood stability and stress management. Supports Neuroplasticity in ECS-Linked Brain Regions: Not reacting to anger reinforces neural pathways related to emotional regulation, involving areas like the prefrontal cortex rich in CB1 receptors. Over time, this strengthens neural connections in areas where the ECS helps moderate stress, enhancing emotional control and conserving ECS tone. Preserves ECS Function for Other Bodily Processes: Avoiding unnecessary emotional reactions leaves more ECS resources available for other critical functions, like immune response, appetite regulation, and sleep. By not "burning through" endocannabinoids with anger, we allow the ECS to contribute to these other processes and help maintain overall health. In this way, choosing not to engage with anger doesn’t just rewire the brain for greater emotional resilience but also conserves our endocannabinoid resources, helping to heal and maintain our ECS tone. This conservation is a powerful tool for restoring balance, as a well-regulated ECS is essential to mental and physical well-being. Balancing the ECS means we have a better chance of living a longer, healthier life. When we experience anger, our brain responds as if we’re under threat, activating our stress response. This response directly impacts the ECS, mainly through the rapid use of anandamide. It puts the system into hyperdrive when it's depleted by trying to settle the mind without the bliss molecule. -Mike Robinson, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)

Q: When I show love and feel that emotion, does that help my ECS? A: YES. Showing love and compassion to others can stimulate the release and circulation of anandamide, the "bliss molecule." Studies on positive social interactions and compassion practices and their effects on the brain’s reward systems, where the ECS plays a crucial role, have observed this process. Let's break it down... Social Connection and Anandamide Release: When we show love or kindness, our body often responds by releasing endocannabinoids like anandamide. Research demonstrates that positive social interactions activate the ECS in areas of the brain associated with reward, pleasure, and social bonding—especially the prefrontal cortex, nucleus accumbens, and amygdala. For example, a 2017 study published in Frontiers in Psychology noted that engaging in compassionate acts can increase feelings of connection and well-being, partly regulated by the ECS through anandamide signaling. Oxytocin and the ECS Synergy: Acts of love often release oxytocin, known as the "love hormone," which enhances feelings of trust and bonding. Studies indicate that oxytocin and anandamide are closely linked and can even amplify each other’s effects. A 2019 study in Nature Communications found that oxytocin can increase anandamide levels in the brain’s reward centers, creating a loop that encourages further positive social interaction. This synergistic effect strengthens the ECS’s role in modulating mood and reinforces feelings of bliss. Reduced Stress and Increased Anandamide: Acts of love and kindness also reduce stress, which conserves and promotes the natural production of anandamide. A 2015 study published in Psycho-neuroendocrinology observed that people who regularly engage in loving or altruistic behaviors had lower cortisol (a stress hormone) levels and higher endocannabinoid activity. By lowering stress, loving interactions reduce the need to deplete anandamide, helping it circulate longer in the brain and contributing to feelings of calm and happiness. Meditation and Compassion Practices: Loving-kindness meditation (LKM), which involves mentally sending love and goodwill to oneself and others, has also been shown to increase endocannabinoid levels, particularly anandamide. A study in 2016 found that individuals practicing LKM experienced increased activity in brain regions rich in CB1 receptors, where anandamide binds to produce effects related to mood and pleasure. These findings suggest that practices focused on love and compassion can boost the ECS, leading to greater anandamide release and empowering individuals to take control of their well-being. So show love and try to ignore anger. Your ECS is at risk of suffering when you pay too?much attention to negative things, and it gains so much when you focus on the positive! -Mike Robinson, founder Nanobles Corp. / Global Cannabinoid Research Center (GCRC)